By analyzing the DNA and RNA of lung cancers, researchers at the University of Michigan Comprehensive Cancer Center have found that patients whose tumors contained a large number of gene fusions had worse outcomes than patients with fewer gene fusions. Gene fusions are a type of genetic anomaly found in cancers that occurs when genes get rearranged and fuse together. In addition, the researchers identified several new genetic anomalies that occur in lung cancer, including in patients with a history of smoking. The study appears in Nature Communications.
The study looked at 753 lung cancer samples that represented both smokers and non-smokers. Researchers found 6,348 unique fusions with an average of 13 fusions per tumor sample. Anomalies in two gene pathways were most prevalent: the Hippo pathway, which has previously been linked to some rare cancers, and NRG1, which has not previously been seen in cancer.
Researchers know that three common gene fusions—involving ALK, RET and ROS—play a role in about five percent of lung cancers, but primarily in nonsmokers. The new anomalies were found only in patients who did not have ALK, RET, or ROS fusions.
Drug companies are already investigating drugs that could target the Hippo pathway and NRG1. The research team suggests exploring these inhibitors as potential therapeutics in lung cancer.
In addition, the finding that the number of gene fusions was tied to prognosis suggests that a screen could be developed to help doctors determine how aggressive a patient’s tumor is likely to be, and to tailor treatment accordingly.
The study identified many different gene fusions that comprise the landscape of lung cancer, with most occurring in only a small number of individual tumor samples. The Hippo pathway fusions were present in three percent of patients and NRG1 fusions in four percent. The researchers suggest expanding lung cancer subtypes based on these molecular characteristics.Read the study abstract at the Nature Communications website